- No FAQs found
- ABL Kinase Domain Mutation in CML, Cell-based
- ABO Group and Rh Type
- Acid-Fast Bacillus (AFB) Identification, Sequencing and Stain, Paraffin Block
- ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
- Alcohol Metabolites, Quantitative, Urine
- Alpha-Globin Common Mutation Analysis
- Alpha-Globin Gene Deletion or Duplication
- Alpha-Globin Gene Sequencing
- Anti-Müllerian Hormone AssessR™
- Anti-PF4 and Serotonin Release Assay (SRA) for Diagnosing Heparin-induced Thrombocytopenia/Thrombosis (HIT/HITT)
- Antiphospholipid Antibodies
- ASCVD Risk Panel with Score
- Autoimmune Epilepsy Evaluation
- Autoimmune Diseases, Tests for
- Bordetella pertussis toxin (PT) antibody
- B-cell and T-cell Clonality Assays by PCR
- B-Type Natriuretic Peptide (BNP)
- BCR-ABL1 Gene Rearrangement, Quantitative PCR
- Beta-Globin Complete
- Biotin: Interference with Laboratory Assays
- BRCAvantage®, Ashkenazi Jewish Screen
- BRCAvantage®, Rearrangements
- BRCAvantage™, Comprehensive
- BRCAvantage™, Single Site
- CDH1 Sequencing and Deletion/Duplication
- Clostridium difficile Diagnostic Testing
- C1 Inhibitor, Protein and Functional Tests
- Calreticulin (CALR) Mutation Analysis
- Carbapenem Resistant Enterobacteriaceae Culture Screen
- Cardio IQ Lipoprotein Fractionation, Ion Mobility
- CardioIQ® Insulin Resistance Panel with Score
- Cervical Cancer, TERC, FISH
- CFvantage® Cystic Fibrosis Expanded Screen
- Chlamydia trachomatis, TMA
- Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA
- Chromosomal Microarray, POC, ClariSure®, Oligo-SNP
- Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP
- Chromosome Analysis and AFP with Reflex to AChE, Fetal Hgb, Amniotic Fluid
- Chromosome Analysis, Amniotic Fluid
- Chromosome Analysis, Blood
- Chromosome Analysis, Blood with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Chorionic Villus Sample
- Chromosome Analysis, High Resolution
- Chromosome Analysis, High Resolution with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Mosaicism
- Chromosome Analysis, Neonatal Blood
- Chromosome Analysis, Sister Chromatid Exchange
- Chromosome Analysis, Tissue
- Chromosome DEB Assay for Fanconi anemia
- Chronic Lymphocytic Leukemia (CLL) - Diagnostic and Prognostic Testing
- Culture, Fungus
- Culture, Urine, Routine
- Cystic Fibrosis Screen
- Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) PCR
- Cytomegalovirus (CMV) IgG avidity
- D-Dimer, Quantitative
- Dementia, Secondary Causes
- Dengue Virus Testing
- Diabetes Risk Panel with Score and Cardio IQ® Diabetes Risk Panel with Score
- Diagnosis of Intestinal Parasites
- Drug Testing, General Toxicology (Blood, Urine, or Serum)
- Drug Toxicology Alcohol Metabolite, with Confirmation, Oral Fluid
- Drug Toxicology Monitoring, Oral Fluid Testing
- Factor V (Leiden) Mutation Analysis
- Factor VIII Activity, Clotting
- Familial Hypercholesterolemia (FH) Panel
- Familial Hypercholesterolemia (FH) Single Site
- Familial Mediterranean Fever Mutation Analysis
- First Trimester Screen, hCG
- First Trimester Screen, Hyperglycosylated hCG (h-hCG)
- FISH, Angelman
- FISH, MET Amplification
- FISH, Myeloma, 17p-, rea 14q32 with Reflexes
- FISH, Prader-Willi
- FISH, Prenatal Screen
- No FAQs found
- Helicobacter pylori (H pylori) Antibody Discontinuation
- Heparin, Anti-Xa
- Hepatitis B Surface Antibody, Quantitative
- Hepatitis B Surface Antigen, Quantitative, Monitoring
- Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype
- Hepatitis C Viral RNA Genotype 1 NS5A Drug-resistance
- Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance
- Hepatitis C Viral RNA NS3 Drug Resistance
- Hepatitis C Viral RNA, Genotype, LiPA
- Hepatitis C Virus Antibody and RNA Testing
- Hereditary Cancer Panels: MYvantageTM Hereditary Comprehensive Cancer Panel and GIvantageTM Hereditary Colorectal Cancer Panel
- Hereditary Hemochromatosis DNA Mutation Analysis
- Herpes Simplex Virus (HSV) Type-Specific IgG Antibodies
- Herpes Simplex Virus Type 2 (HSV-2) IgG Inhibition, ELISA
- HIV Pre-exposure Prophylaxis (PrEP) Testing
- HIV-1 Coreceptor Tropism, Proviral DNA
- HIV-1 Coreceptor Tropism, Ultradeep Sequencing
- HIV-1 Integrase Genotype
- HIV-1 Resistance, Proviral DNA (RTI, PI, Integrase Inhibitors)
- HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
- HPV mRNA E6/E7
- Infliximab and Adalimumab Drug and Anti-drug Antibody Testing
- Influenza A and B Antigen, Immunoassay
- Influenza Type A and B Antibodies
- Insulin, Intact, LC/MS/MS
- Integrated Screen, Part 1
- Integrated Screen, Part 2
- Intrinsic Factor Blocking Antibody
- No FAQs found
- No FAQs found
- LDL Cholesterol Calculations
- LeukoVantage® Myeloid Neoplasm Mutation Panels
- Lupus Anticoagulant (LA) Evaluation with Reflex
- Maternal Serum AFP
- Melanoma, BRAF V600E and V600K Mutation Analysis, THxID®
- Metanephrines, Fractionated, Free, LC/MS/MS, Plasma
- Methylenetetrahydrofolate Reductase (MTHFR), DNA Analysis
- Microalbumin (Urinary Albumin Excretion)
- Myeloproliferative Neoplasm Diagnosis: Molecular Evaluation
- No FAQs found
- Pain Management and CYP2D6/CYP2C19
- Pain Management Antidepressants, With Confirmation, Urine
- Pain Management Antipsychotics, With Confirmation, Serum and Urine
- Pain Management, Naltrexone, Quantitative, Urine
- Partial Thromboplastin Time, Activated (aPTT)
- Penta Screen
- Pharmacogenomics Panel
- PIK3CA Mutation Analysis
- Platelet Antibody Screen (Indirect)
- PNH with FLAER (High Sensitivity)
- Prothrombin Time with INR
- PTH, Intact and Calcium
- Streptococcus pneumoniae (Pneumococcal) Antibody Tests
- Saccharomyces cerevisiae Antibodies (ASCA) (IgG, IgA)
- Sequential Integrated Screen, Part 1
- Sequential Integrated Screen, Part 2
- Serum Integrated Screen, Part 1
- Serum Integrated Screen, Part 2
- Serum Pregnancy Tests
- Sickle Cell Screen
- Stepwise, Part 1
- Stepwise, Part 2
- SureSwab® Trichomonas vaginalis RNA, Qualitative TMA
- SureSwab®, Candidiasis, PCR
- TP53 Sequencing and Deletion/Duplication
- T4, Free
- Tamoxifen and Metabolites, LC-MS/MS
- Testosterone Testing
- Total Testosterone, LC/MS/MS
- Triple Screen
- No FAQs found
- No FAQs found
- No FAQs found
LDL Cholesterol CalculationsTest code(s) 7600, 14852(X), 19543, 92061, 92145, 91716, 92052, 92053
Question 1. Why is LDL-cholesterol important?
The level of low-density lipoprotein-cholesterol (LDL-C), among other factors, correlates with the likelihood of developing atherosclerotic cardiovascular disease (ASCVD). Thus, LDL-C measurement is useful for assessing ASCVD risk, stratifying individuals into treatment benefit groups, and monitoring risk-reduction therapy.1
Question 2. How is LDL-C measured?
LDL-C is most often measured indirectly, using a calculation based on other blood lipid analytes. Historically, the Friedewald calculation2 has been the most common approach. This equation, developed in the 1970s, incorporates total cholesterol, HDL-cholesterol (HDL-C), and triglyceride concentrations:
LDL-C (mg/dL) = total cholesterol – HDL-C – (triglycerides/5),
where “triglycerides/5” is used to represent very low-density lipoprotein-C (VLDL-C).
LDL-C concentration can also be measured directly or with newer equations. Quest Diagnostics uses the Martin-Hopkins calculation, as described below, which provides accurate quantitation even in patients with triglyceride (TG) values between 200 mg/dL and 400 mg/dL and LDL-C levels below 70 mg/dL.
Question 3. Why does Quest no longer rely on the Friedewald equation?
Although the Friedewald equation it is still widely used and generally produces reliable results, it may underestimate LDL-C at the low LDL-C levels that modern treatment guidelines call for and therapies can achieve (eg, <70-100 mg/dL).3 PCSK-9 inhibitors can drive LDL-C levels even lower (eg, <40 mg/dL). Such low LDL-C concentrations are below the concentrations considered when the Friedewald equation was developed.2
This limitation relates to the fact that the Friedewald equation uses a fixed ratio of triglyceride to VLDL-C; it does not allow for heterogeneity in the ratio of triglycerides to VLDL-C. This becomes a problem especially at lower LDL-C and higher triglyceride concentrations, when the Friedewald calculation tends to underestimate LDL-C. In a 2013 study, Martin and colleagues compared the results of direct LDL-C and calculated LDL-C using the Friedewald equation in more than 1.3 million U.S. adults.4 Friedewald-estimated LDL-C tended to be lower than directly measured LDL-C, especially in patients with calculated LDL-C levels below 100 mg/dL. At triglyceride levels ≥150 mg/dL, calculated LDL-C was often below <70 mg/dL in patients with directly measured LDL-C in the 71-80 mg/dL range. These findings suggest that the tendency of the Friedewald equation to underestimate LDL-C at higher triglyceride and lower LDL-C levels could result in high-risk patients being undertreated.
Question 4. How does the Martin-Hopkins calculation differ from the Friedewald calculation for LDL-C?
The Martin-Hopkins calculation provides greater customization to a patient’s specific triglyceride level by using a more “personalized” factor to calculate VLDL-C from triglycerides.4 This adjustable factor, which can range from 3.1 to 11.9, was derived from an analysis of triglyceride-to-VLDL-C ratios in more than 1.3 million people.4 The factor is lowest for patients with very low levels of triglyceride and high levels of non-HDL-cholesterol (total cholesterol – HDL-C), and highest for those with very high levels of triglyceride and low levels of non-HDL-cholesterol.
Question 5. How does the Martin-Hopkins calculation compare with the Friedewald calculation and direct LDL-C measurement?
Compared with the Friedewald equation, the Martin-Hopkins calculation provides better correlation with direct LDL-C measurements.3-7 Concordance with guideline-based risk classification, especially at high triglyceride and low LDL-C, is also superior using the Martin-Hopkins calculation.3-7 In the 2013 validation study mentioned above,4 the improvement was greatest for people with estimated LDL-C levels below 70 mg/dL, especially those with higher triglyceride levels (see Table). Thus, the primary advantage of the Martin-Hopkins equation is that it is applicable to low LDL-C levels even in the presence of elevated triglyceride concentrations.
The improved accuracy at low LDL-C allows more accurate assessment of patients in the high-risk categories undergoing aggressive treatment with low LDL goals. In addition, the ability to adjust for high triglyceride levels may improve reliability of LDL-C estimation when fasting is not desired or practical.8 This can be convenient for risk assessment, especially for patients who have difficulty fasting (eg, young children and people with diabetes).8
Question 6. Is fasting required when using the Martin-Hopkins calculation?
The need for fasting varies with the indication for testing, and the method used to calculate LDL-C should not affect the decision to require fasting samples. However, as noted above, the ability of the Martin-Hopkins calculation to adjust for high triglyceride levels may also make LDL-C estimation more reliable in nonfasting patients.8
Question 7. My patient’s LDL cholesterol concentration could not be calculated because the triglycerides were too high (>4.35 mmol/L; >400 mg/dL). What options do I have for getting an LDL cholesterol concentration?
If the LDL concentration could not be calculated because the triglyceride level was too high, direct LDL-C testing may be useful. Direct LDL measurement provides a reliable result even when triglyceride levels are up to 1,000 mg/dL. It can be ordered as a stand-alone test, as a reflex if the patient’s triglyceridelevel is likely to exceed 400 mg/dL, or as part of one of several panels. The table below lists tests and panels that include direct LDL-C measurement or reflex to direct LDL-C measurement when the triglyceride level is above 400 mg/dL:
Question 8. Does Quest offer advanced lipid testing options to assess ASCVD risk?
Yes. Aside from standard lipid profile tests, Quest offers several advanced lipid testing options, including measurement of LDL particle number and size. In a number of retrospective analyses, lipoprotein subfractions have been found to be associated with CVD events.9,10 Additionally, particle numbers as determined by ion mobility were found to be a significant determinant in defining residual risk.11 Quest uses ion mobility separation of subfractions for these measurements. The ion mobility method directly measures particle size and concentration, unlike other approaches that use algorithms to indirectly calculate lipid subfractions.12 And, unlike some methods, ion mobility separation of subfractions does not cause lipoprotein modification that could potentially affect the accuracy of the assay.10,13 Ion mobility has been used in multiple lipoprotein studies9,10,14 and is the method used in the Cardio IQ Lipoprotein Fractionation, Ion Mobility test (Test Code 91604).
- Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1-45.
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
- Quispe R, Hendrani A, Elshazly MB, et al. Accuracy of low-density lipoprotein cholesterol estimation at very low levels. BMC Med. 2017;15:83.
- Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310:2061-2068.
- Meeusen JW, Lueke AJ, Jaffe AS, et al. Validation of a proposed novel equation for estimating LDL cholesterol. Clin Chem. 2014;60:1519-1523.
- Lee J, Jang S, Son H. Validation of the Martin method for estimating low-density lipoprotein cholesterol levels in Korean adults: findings from the Korea National Health and Nutrition Examination Survey, 2009-2011. PLoS One. 2016;11:e0148147.
- Chaen H, Kinchiku S, Miyata M, et al. Validity of a novel method for estimation of low-density lipoprotein cholesterol levels in diabetic patients. J Atheroscler Thromb. 2016;23:1355-1364.
- Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cutpoints-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem. 2016;62:930-946.
- Musunuru K, Orho-Melander M, Caulfield MP, et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol. 2009;29:1975-1980.
- Mora S, Caulfield MP, Wohlgemuth J, et al. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Circulation. 2015;132:2220-2229.
- Melander O, Shiffman D, Caulfield MP, et al. Low-Density Lipoprotein Particle Number Is Associated With Cardiovascular Events Among Those Not Classified Into Statin Benefit Groups. J Am Coll Cardiol. 2015;65:2571-2573.
- Caulfield MP, Li S, Lee G, et al. Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin Chem. 2008;54:1307-1316.
- Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010;21:305-311.
- Krauss RM, Pinto CA, Liu Y, et al. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin. J Clin Lipidol. 2015;9:93-102.
Version 0 effective 02/13/2017 to 08/21/2017